阿匹氯铵 | 34959-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 阿匹氯铵
• 中文别名: 艾查斯氯铵
• 英文名称: 4,11-dimethoxy-9-methylene-5-oxo-8,9-dihydro-5H,6H-spiro[furo[3',2':6,7]chromeno[3,2-c]pyridinium-7,1'-piperidinium]; chloride
• 英文别名: 4,11-Dimethoxy-9-methylene-5-oxo-8,9-dihydro-5H,6H-spiro<3',2':6,7>chromeno<3,2-c>pyridine-7,1'-piperidinium> chloride；azaspirium chloride；11,17-dimethoxy-4-methylidenespiro[2,15-dioxa-6-azoniatetracyclo[8.7.0.03,8.012,16]heptadeca-1(17),3(8),10,12(16),13-pentaene-6,1'-azinan-1-ium]-9-one;chloride
• CAS: 34959-30-3
• 化学式: C₂₂H₂₄NO₅*Cl
• 分子量: 417.889
• InChiKey: PYNSMGBGABAWPB-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.09
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  57.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  阿匹氯铵 在 palladium on activated charcoal 氢气 作用下， 以 溶剂黄146 为溶剂， 生成 4,11-dimethoxy-9-methyl-5-oxo-8,9-dihydro-5H,6H-spiro[furo[3',2':6,7]chromeno[3,2-c]pyridinium-7,1'-piperidinium]; chloride
  参考文献：
  名称：

  叔丁酮，4-氨基，51氨基烷基

  摘要：

  死Aminoalkylierung冯2- Methylchromonen（1B，电子sowie 2B，C）führtつ苯并吡喃并〔3.2- c ^ ]吡啶chloriden（9A - d sowie 11A - ë）。

  DOI：

  10.1002/cber.19741070334
• 作为产物：
  描述：

  聚合甲醛 、 凯林 、 哌啶盐酸盐 以 硝基苯 、 苯 为溶剂， 生成 阿匹氯铵
  参考文献：
  名称：

  叔丁酮，4-氨基，51氨基烷基

  摘要：

  死Aminoalkylierung冯2- Methylchromonen（1B，电子sowie 2B，C）führtつ苯并吡喃并〔3.2- c ^ ]吡啶chloriden（9A - d sowie 11A - ë）。

  DOI：

  10.1002/cber.19741070334

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX
  申请人：ALTANA Pharma AG

  公开号：EP1341527A1

  公开（公告）日：2003-09-10
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.